ScoreWhy is Prelude Therapeutics, Inc. ?
1
Positive results in Sep 25
- NET SALES(HY) At USD 6.5 MM has Grown at 116.67%
- OPERATING CASH FLOW(Y) Highest at USD -100.16 MM
- RAW MATERIAL COST(Y) Fallen by -8.14% (YoY)
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 347.35%, its profits have risen by 15%
3
High Institutional Holdings at 93.63%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
- Their stake has increased by 1.04% over the previous quarter.
4
Market Beating Performance
- The stock has generated a return of 347.35% in the last 1 year, much higher than market (S&P 500) returns of 11.87%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Prelude Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Prelude Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Prelude Therapeutics, Inc.
347.35%
-0.11
201.92%
S&P 500
11.87%
0.62
19.30%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
62.98%
EBIT Growth (5y)
-185.24%
EBIT to Interest (avg)
-118.58
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.93
Sales to Capital Employed (avg)
0.08
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
93.63%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.61
EV to EBIT
-1.32
EV to EBITDA
-1.34
EV to Capital Employed
25.27
EV to Sales
15.17
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1920.19%
ROE (Latest)
-190.95%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend19What is working for the Company
NET SALES(HY)
At USD 6.5 MM has Grown at 116.67%
OPERATING CASH FLOW(Y)
Highest at USD -100.16 MM
RAW MATERIAL COST(Y)
Fallen by -8.14% (YoY
OPERATING PROFIT(Q)
Highest at USD -19.99 MM
PRE-TAX PROFIT(Q)
Highest at USD -19.73 MM
NET PROFIT(Q)
Highest at USD -19.73 MM
EPS(Q)
Highest at USD -0.26
-5What is not working for the Company
ROCE(HY)
Lowest at -103.99%
DEBT-EQUITY RATIO
(HY)
Highest at -63.39 %
CASH AND EQV(HY)
Lowest at USD 128.17 MM
Here's what is working for Prelude Therapeutics, Inc.
Net Sales
At USD 6.5 MM has Grown at 116.67%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Operating Cash Flow
Highest at USD -100.16 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Operating Profit
Highest at USD -19.99 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD -19.73 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD -19.73 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD -0.26
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Raw Material Cost
Fallen by -8.14% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Prelude Therapeutics, Inc.
Debt-Equity Ratio
Highest at -63.39 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Cash and Eqv
Lowest at USD 128.17 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
